the-gut-microbiome-associates-with-phenotypic-manifestations-of-long-covid.md

Summary of The gut Microbiome Associates with Phenotypic Manifestations of Post-Acute COVID-19 Syndrome

Source and Special thanks to Reddit User kwil2

• ENTEROTYPE 1
  • gut-biome characteristics
    • a low count of
      • Bifidobacterium adolescentis and
    • high count of
      • Clostridium bolteae,
      • Clostridium symbiosum,
      • Ruthenibacterium lactatiformans, and
      • Ruminococcus gnavus.
  • symptoms
    • fatigue,
    • muscle pain,
    • shortness of breath,
    • cough,
    • runny nose,
    • "sadness", and
    • chest pain.
  • disruptions in the following biologic processes:
    • Glycolosis IV;
    • Methylerythritol Phosphate Pathway;
    • S-Adenosyl-L-Methionine Salvage I;
    • Inosine 5-Phosphate Degradation;
    • Guanosine Ribonucleotide Biosynthesis;
    • L-Isoleucine Biosynthesis III;
    • Chorismate Biosynthesis I;
    • Aromatic Amino Acid Biosynthesis;
    • UMP Biosynthesis I, II, and III; and
    • tRNA Charging.
  • To a lesser degree, disruptions in the following additional biologic processes:
    • Sucrose Biosynthesis II;
    • Glycogen Degradation II; and
    • L-Valine Biosynthesis.
• ENTEROTYPE 2
  • gut-biome characteristics
    • low count of
      • Bifidobacterium pseudocatenulatum and
      • Bifidobacterium longum
    • high count of
  • symptoms
    • fatigue,
    • brain fog,
    • memory loss,
    • anxiety,
    • insomnia, and
    • general unwellness.
  • disruptions in the following biologic processes:
    • Adenine and Adenosine Salvage III;
    • Calvin-Benson-Bassham Cycle;
    • Purine Ribonucleosides Degradation;
    • 5 Aminoimidazole Ribonucleotide Biosynthesis;
    • 5 Aminoimidazole Ribonucleotide Biosynthesis I and III;
    • L-Lysine Biosynthesis III and VI;
    • L-Isoleucine Biosynthesis I;
    • L-Lysine, L-Threonine, L-Methionine Biosynthesis II;
    • Inosine-5-Phosphate Biosynthesis I;
    • L-Histadine Biosynthesis;
    • CDP-Diacylglycerol Biosynthesis I and II;
    • L-Ornithine Biosynthesis I;
    • Adenosine Nucleotides de novo Biosynthesis I;
    • L-Methionine Biosynthesis IV;
    • L-Threonine Biosynthesis;
    • O-Antigen Building Blocks (E coli) Biosynthesis; and
    • L-Phenylalanine Biosynthesis
  • To a lesser degree, disruptions in the following additional biologic processes:
    • Homolactic Fermentation;
    • Glycolysis II (from fructose and 6-phosphate);
    • Stachyose Degradation;
    • Pentose Phophate Pathway (non-oxydative branch) I;
    • Myo- Chiro-Scyllo-Inositol Degradation;
    • Purine Nucleotides de novo Biosynthesis I;
    • UDP-N-acetyl-D-Glucosamine Biosynthesis I;
    • Thiamine Diphosphate (Eukaryotes) Biosynthesis III;
    • L-Serine and Glycine Biosynthesis I; and
    • Adenosine Nucleotides de novo Biosynthesis II.
• ENTEROTYPE 3
  • gut-biome characteristics
    • low count of
      • Bacteroides uniformis,
      • Bilophilia wadsworthia, and
      • Holdemania filiformis.
  • symptoms
    • memory loss,
    • joint pain,
    • headache,
    • palpitations, and
    • bloating.
  • disruptions in the following biologic processes:
    • Pyruvate to Acetate and (S) Lactate I and II.
  • To a lesser degree, disruptions in the following additional biologic processes:
    • Glycogen Degradation II;
    • Glycolysis I (from glucose 6-phosphate);
    • L-Valine Biosynthesis;
    • Sucrose Biosynthesis II; and
    • L-Methionine Biosynthesis III.